Home Newsletters Pancreatic Cell News CRISPR Therapeutics and ViaCyte, Inc. Announce First Patient Dosed in Phase 1...

CRISPR Therapeutics and ViaCyte, Inc. Announce First Patient Dosed in Phase 1 Clinical Trial of Novel Gene-Edited Cell Replacement Therapy for Treatment of Type 1 Diabetes (T1D)

By
Justin.choi
-
0
CRISPR Therapeutics and ViaCyte, Inc. announced the first patient has been dosed in the Phase I clinical trial of VCTX210 for the treatment of type I diabetes.
[CRISPR Therapeutics]
6445212 BBBBBBBB items 1 apa 0 default asc 1 171566 https://www.stemcellsciencenews.com/wp-content/plugins/zotpress/
Press Release

RELATED ARTICLES

Exit mobile version